



Airdoc 鷹瞳

Beijing Airdoc Technology Co., Ltd.

北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code : 2251

2022 INTERIM REPORT

Contents

2	Corporate Information
4	Financial Summary
5	Management Discussion and Analysis
18	Other Information
27	Review Report
28	Consolidated Statement of Profit or Loss
29	Consolidated Statement of Profit or Loss and Other Comprehensive Income
30	Consolidated Statement of Financial Position
32	Consolidated Statement of Changes in Equity
34	Condensed Consolidated Cash Flow Statement
35	Notes to the Unaudited Interim Financial Report
44	Definitions and Glossary of Technical Terms



Corporate Information

BOARD OF DIRECTORS

Executive Directors

Mr. ZHANG Dalei (張大磊)
(Chairman and chief executive officer)
Mr. GAO Fei (高斐)
Dr. CHEN Yuzhong (陳羽中)
Mr. CHEN Hailong (陳海龍)

Non-executive Directors

Mr. JIANG Bo (蔣波) *(ceased from May 19, 2022)*
Mr. CHEN Xin (陳欣) *(effective from May 19, 2022)*
Ms. WANG Mi (王謐)

Independent Non-executive Directors

Mr. NG Kong Ping Albert (吳港平)
Mr. WU Yangfeng (武陽豐)
Mr. HUANG Yanlin (黃彥林)

SUPERVISORS

Mr. WEI Yubo (魏宇博)
Ms. BAI Huihui (白惠惠)
Ms. ZHOU Wenjuan (周雯娟)
(ceased from March 17, 2022)
Dr. LUO Ting (羅婷) *(effective from May 19, 2022)*

AUDIT COMMITTEE

Mr. NG Kong Ping Albert (吳港平) *(Chairman)*
Mr. HUANG Yanlin (黃彥林)
Mr. WU Yangfeng (武陽豐)

REMUNERATION AND APPRAISAL COMMITTEE

Mr. HUANG Yanlin (黃彥林) *(Chairman)*
Mr. GAO Fei (高斐)
Mr. NG Kong Ping Albert (吳港平)

NOMINATION COMMITTEE

Mr. ZHANG Dalei (張大磊) *(Chairman)*
Mr. HUANG Yanlin (黃彥林)
Mr. WU Yangfeng (武陽豐)

STRATEGY COMMITTEE

Mr. ZHANG Dalei (張大磊) *(Chairman)*
Mr. NG Kong Ping Albert (吳港平)
Mr. WU Yangfeng (武陽豐)

AUTHORIZED REPRESENTATIVES

Mr. ZHANG Dalei (張大磊)
Ms. SO Lai Shan (蘇麗珊)

JOINT COMPANY SECRETARIES

Ms. YANG Wenting (楊文婷)
Ms. SO Lai Shan (蘇麗珊) *(ACG (CS, CGP) HKACG (CS, CGP))*

HEAD OFFICE, REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Room 21, 4th Floor, Building 2, A2 Yard
West Third Ring North Road
Haidian District
Beijing
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1901, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

H SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong



Corporate Information (Continued)

HONG KONG LEGAL ADVISER

Kirkland & Ellis
26/F, Gloucester Tower
The Landmark
15 Queen's Road Central
Hong Kong

STOCK CODE

2251

COMPANY WEBSITE

www.airdoc.com

PRC LEGAL ADVISER

Zhong Lun Law Firm
22-31/F, South Tower of CP Center
20 Jin He East Avenue
Chaoyang District
Beijing
PRC

AUDITOR

KPMG
*Public Interest Entity Auditor registered in accordance
with the Financial Reporting Council Ordinance*
8th Floor, Prince's Building
10 Chater Road, Central
Hong Kong

COMPLIANCE ADVISOR

Somerley Capital Limited
20/F, China Building
29 Queen's Road Central
Hong Kong

Financial Summary

A summary of the results and of the assets and liabilities of the Group for the Reporting Period together with the comparative figures for the corresponding previous period is set out as follows:

	Six months ended June 30,	
	2022 (Unaudited) RMB'000	2021 (Audited) RMB'000
Revenue	37,407	49,477
Cost of sales	(15,336)	(17,774)
Gross profit	22,071	31,703
Loss from operations	(99,492)	(37,052)
Loss before taxation	(99,684)	(37,154)
Loss for the period	(99,684)	(37,490)
Loss per share		
Basic and diluted (RMB)	(0.98)	(0.50)
	As of June 30, 2022 (Unaudited) RMB'000	As of December 31, 2021 (Audited) RMB'000
Financial Position		
Non-current assets	51,158	48,566
Current assets	1,743,070	1,845,611
Non-current liabilities	3,648	3,420
Current liabilities	50,786	70,771
Net assets	1,739,794	1,819,986
Total equity attributable to equity shareholders of the Company	1,739,794	1,819,986

Management Discussion and Analysis

BUSINESS OVERVIEW

We are an AI-based medical device company with an advanced platform of AI-empowered retina-based deep learning algorithms. Founded in 2015, we are one of the first to provide AI-empowered retina-based early detection, diagnosis and health risk assessment solutions in China. With the feature of integrated software and hardware solutions, we provide our AI-based SaMDs, health risk assessment solutions and hardware devices to a wide range of healthcare environments, enabling us to commercialize and sell not only to clinical departments in hospitals, but also to other types of medical institutions, various consumer healthcare environments and eye health management settings. With an aim to efficiently penetrating our integrated AI-based software and hardware solutions into these healthcare environments, we developed a multi-faceted sales and marketing strategy by establishing three closely connected business units: Airdoc Medical (鹰瞳医疗), Airdoc Health (鹰瞳健康) and Airdoc Eye Health (鹰瞳眼健康). Leveraging retinal imaging, multimodal data analyses and AI deep learning algorithms, our solutions differ from the traditional early detection and diagnosis method by adopting a non-invasive, accurate, fast, effective and scalable detection and diagnosis of chronic diseases. Our Airdoc-AIFUNDUS (1.0), an AI-based SaMD approved for auxiliary diagnosis of diabetic retinopathy in August 2020, was the first of its kind that obtained the Class III medical device certificate from the NMPA. In the first six months of 2022, we had detected over 1.6 million cases via our SaMDs and health risk assessment solutions.

Our Portfolio

To address the largely unmet medical needs of early detection and diagnosis of chronic diseases, we developed our AI-empowered retina-based early detection, diagnosis and health risk assessment solutions potentially capable of covering a wide range of diseases and lesions. Our portfolio includes SaMDs for detection and diagnosis, health risk assessment solutions and hardware devices, forming an integrated solution of AI-based software and hardware. The following diagram sets forth key details of our portfolio as of the date of this interim report:

Product Type	Product	Indication	Class Of Medical Device	R&D Stage		Registration Stage			Expected timeline for the next milestone	Expected NMPA Registration Certificate Application
				Early-stage Development ¹	Late-stage Development ²	Registrational Trial	NMPA Submission	NMPA Approval		
SaMDs for Detection and Diagnosis	Airdoc-AIFUNDUS	Ver. 1.0	Diabetic retinopathy	Class III	[Progress bar]					Approved in August 2020
			Hypertensive retinopathy		[Progress bar]					
		Ver. 2.0	Retinal vein occlusion	Class III	[Progress bar]					Q3 2022
		Age-related macular degeneration (AMD)		[Progress bar]						
		Pathological myopia		[Progress bar]						
		Retinal detachment	Class III	[Progress bar]					Q2 2023	
		Glaucoma detection	Class II	[Progress bar]					Approved in June 2020	
		Cataracts detection	Class II	[Progress bar]					Approved in January 2022	
	Individual Products		ICVD / ASCVD	Class III	[Progress bar]					Q4 2023
			Gestational diabetic retinopathy	Class III	[Progress bar]					Q1 2025
		Gestational hypertensive retinopathy	Class III	[Progress bar]					Q1 2025	
		Papilledema intracranial hypertension retinopathy	Class III	[Progress bar]					Q4 2023	
		Anemia	Class II	[Progress bar]					Q4 2022	
Health Risk Assessment Solutions ³	55 types of lesions and diseases ⁴			[Progress bar]						
	Hyperthyroidism			[Progress bar]						
	Graves ophthalmopathy (external eye)			[Progress bar]						
	Retinal vein occlusion (prediction)			[Progress bar]						
	Dementia			[Progress bar]						
	Parkinson's disease			[Progress bar]						
	Atrial fibrillation			[Progress bar]						
	Arteriosclerosis (middle or large artery)			[Progress bar]						
Proprietary Hardware Device	AI-FUNDUSCAMERA-P		Class II	[Progress bar]					Approved in March 2021	
	AI-FUNDUSCAMERA-D		Class II	[Progress bar]					Approved in July 2022	
	AI-FUNDUSCAMERA-M		Class II	[Progress bar]					Q2 2023	

Our Core Product



Management Discussion and Analysis (Continued)

Notes:

1. Denotes the process of data collection, data labelling and model training.
2. Denotes the process of data supplementation, algorithm training iteration and algorithm validation.
3. No regulatory approval or registration is required for the sales of our health risk assessment solutions in consumer healthcare environments and eye health management settings.
4. During the Reporting Period, we offer health risk assessment solutions with the ability to detect risk indicators, including risk assessments of retinal abnormalities, retinal vascular, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease and anemia.
5. Denotes the process of product planning, product definition, engineering verification and design verification.
6. Denotes the process of production verification.

SaMDs for Detection and Diagnosis

We have Airdoc-AIFUNDUS, our in-house developed Core Product, and a pipeline of seven other in-house developed individual SaMDs in our SaMD portfolio.

Airdoc-AIFUNDUS — Our Core Product

Our Airdoc-AIFUNDUS is an AI-based SaMD that uses sophisticated deep learning algorithms to accurately detect and diagnose chronic diseases from retinal images. We developed Airdoc-AIFUNDUS based on our proprietary AI-empowered retina-based early detection, diagnosis and health risk assessment technology platform, which is driven by deep learning technologies and fully validated in terms of scientific theory, clinical trial data and clinical pathway.

We have three versions of Airdoc-AIFUNDUS. Our Airdoc-AIFUNDUS (1.0) was the first AI-empowered retina-based auxiliary diagnosis product that obtained the Class III medical device certificate from the NMPA for assisting physicians in medical institutions with detecting and diagnosing diabetic retinopathy. In our multi-center clinical trial with 1,000 enrolled patients, our Airdoc-AIFUNDUS (1.0) demonstrated an industry-leading sensitivity of 91.75% and specificity of 93.10%. Moreover, our Airdoc-AIFUNDUS (1.0) is widely compatible with most fundus cameras on the market, which enables us to be well-positioned to capture the significant market opportunity. With diabetic retinopathy being the most common diabetes complication, we have marketed our Airdoc-AIFUNDUS (1.0) to the departments of endocrinology, ophthalmology and physical examination in hospitals.

Airdoc-AIFUNDUS (2.0) is designed for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion and age-related macular degeneration. We are conducting the multi-center clinical trial for our Airdoc-AIFUNDUS (2.0). With the enrollment of clinical trial and analysis of retinal images by Airdoc-AIFUNDUS (2.0) already completed, we are currently at the late stage of clinical trial where statistics are being processed. We plan to apply for a registration approval of new indications with the NMPA in the fourth quarter of 2022 once we complete the entire process of clinical trial by the third quarter of 2022. With the NMPA approval of our Airdoc-AIFUNDUS (2.0) in the future, it has the potential to become the first AI-based auxiliary diagnosis SaMD in China with multiple approved indications. After obtaining the registration approval of new indications, we plan to market our Airdoc-AIFUNDUS (2.0) to the departments of cardiovascular and neurology in addition to the departments in hospitals mentioned above and promote it to patients with high blood pressure or at high risk of retinal vein occlusion.



Management Discussion and Analysis (Continued)

Airdoc-AIFUNDUS (3.0) is designed for the auxiliary diagnosis of pathological myopia and retinal detachment to address increasing myopia and vision problems in China, especially in younger generations. We plan to commence the clinical trial for our Airdoc-AIFUNDUS (3.0) in October 2022 and begin to enroll subjects in late 2022 and apply for a registration approval of new indications with the NMPA in the first half of 2024.

Glaucoma Detection SaMD

Our glaucoma detection SaMD is used to process and analyze fundus images to detect glaucoma by measuring the CDR of the optic disc. Featuring high accuracy, objectivity and efficiency, our glaucoma detection SaMD allows an editable and traceable analysis process while enabling physicians to rely less on experience and training to generate the CDR in early detection of glaucoma. We received a Class II medical device registration certificate for our glaucoma detection SaMD from the Shanghai branch of the NMPA in June 2020.

Cataracts Detection SaMD

Our cataracts detection SaMD is designed to detect cataracts by measuring the color value of the eye lens. Our cataracts detection SaMD can help ophthalmologists conveniently detect cataracts in a more standardized and scalable way and facilitate the process of grading cataracts in an accurate and objective fashion. We received the Class II medical device registration certificate for our cataracts detection SaMD from the Shanghai branch of the NMPA in January 2022.

Other SaMDs for Detection and Diagnosis

We are developing five other SaMDs designed for the detection and auxiliary diagnosis, covering ICVD and ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial hypertension retinopathy and anemia based on our AI-empowered retina-based early detection, diagnosis and health risk assessment technology platform.

Health Risk Assessment Solutions

As chronic disease prevalence in China continues to rise, people's health awareness as well as the need for health risk assessment is also rapidly growing. To capture this massive market opportunity, we develop our AI-empowered retina-based health risk assessment solutions that provide end users with basic health assessment and detect risk indicators, including retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular diseases and anemia. Targeting a wide range of business settings that act as entry points of daily health monitoring and eye health management, we customize our health risk assessment solutions to cater to their unique needs raised in different healthcare environments. With our health risk assessment solutions currently covering 55 types of lesions and diseases, we primarily market it to various types of healthcare providers, including health checkup centers, insurance companies, optometry centers and pharmacies. We also plan to expand the coverage of diseases and lesions of our health risk assessment solutions to include hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation and arteriosclerosis, among others.



Management Discussion and Analysis (Continued)

Proprietary Hardware Devices

We have three in-house developed fundus cameras that are compatible with our auxiliary diagnosis SaMDs and health risk assessment solutions, enabling us to provide integrated healthcare solutions that combine hardware and software. Together with our software products, our hardware devices are powered by on-device AI technologies such as speech recognition, speech synthesis and computer vision and can successfully address pain points of existing fundus cameras on the market at a fraction of the cost.

AI-FUNDUSCAMERA-P

Our AI-FUNDUSCAMERA-P is a portable, automatic and self-service fundus camera that can easily apply to any healthcare environments, which is a breakthrough innovation from existing fundus cameras. Our products are operator-free and can complete the retinal image capture automatically while traditional fundus cameras require professionals to operate. We received a Class II medical device certificate for our AI-FUNDUSCAMERA-P from the Shanghai branch of the NMPA in March 2021 and had commenced commercialization since then.

AI-FUNDUSCAMERA-D

Our AI-FUNDUSCAMERA-D is a fully automatic and fully self-service desktop fundus camera with comparable image quality but significantly lower costs than traditional high-end desktop fundus cameras. Its infrared imaging and low-light enhancement technologies facilitate the capture of high-quality images. We recently received the Class II medical device registration certificate for our AI-FUNDUSCAMERA-D from the Shanghai branch of the NMPA in July 2022. We will start to commercialize our desktop version in various healthcare environments to meet the customer's needs for large-sized fundus cameras.

AI-FUNDUSCAMERA-M

Our AI-FUNDUSCAMERA-M is a multimodal health scanner integrated with more biosensors that enable it not only to capture retinal images but also other physiological data, such as electrocardiograms, blood oxygen and blood pressure. The collection of multimodal physiological data serves as the foundation of our AI-based health risk assessment solutions. We expect to apply for a Class II medical device registration certificate for our AI-FUNDUSCAMERA-M in the fourth quarter of 2023.

WARNING UNDER RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET OUR CORE PRODUCT, AIRDOC-AIFUNDUS, OR OUR OTHER PRODUCTS.

R&D

We continue developing AI-empowered retina-based technology to enhance our existing pipeline and to provide comprehensive and multi-faceted high-quality AI-based solutions for chronic disease early detection and diagnosis. We have primarily focused our efforts on developing deep learning algorithms, processing and labeling medical data, developing engineering infrastructures for algorithm training and data analysis, and developing technologies for our hardware devices. As of the date of this interim report, we have developed over 90 deep learning algorithms to cover a comprehensive range of diseases, lesions and health risks.



Management Discussion and Analysis (Continued)

We are one of the few in the industry that offer solutions that integrate software, algorithms, hardware and services together as one product. While our AI-based SaMDs are compatible with various fundus cameras on the market, we believe that our in-house developed hardware devices powered by on-device AI technologies provide an improved user experience, better algorithm optimization with our software, seamless end-to-end performance and greater cost effectiveness that make us the solution-of-choice to customers. During the Reporting Period, we continued developing new algorithms and optimizing existing ones so as to increase screening efficiency, improve diagnosis accuracy and cover more health risks while reducing cloud computing costs. We streamlined, consolidated and upgraded our AI-based product solutions to better cater to our three business pillars: Airdoc Medical, Airdoc Health and Airdoc Eye Health. In addition, we also upgraded our hardware devices in a comprehensive manner that integrates enhancements from hardware itself, algorithms, software and product solutions. We continue reducing hardware costs while enhancing its performance by optimizing the on-device AI-empowered algorithms rather than purely using high-end sophisticated optical components.

As of the date of the interim report, we had quite a few R&D achievements that will reinforce the foundation for our future growth. For example, in May 2022, we jointly published a research paper together with Beijing Tongren Eye Center (北京同仁眼科中心) in The JAMA Network Open regarding the performance of Retinal Artificial Intelligence Diagnosis System (the “RAIDS”) in detecting and screening 10 retinal diseases. The results showed that RAIDS achieved a sensitivity of 89.8% to detect any of 10 retinal diseases and differentiated 10 retinal diseases with accuracies ranging from 95.3% to 99.9%. Compared with human retinal specialists, RAIDS showed a higher sensitivity for detecting retinal abnormality and greater efficiency for assessing retinal images. As a result, the AI-based retinal imaging technology not only may help overcome the lack of experienced ophthalmologists in underdeveloped areas, but also is better positioned to serve the needs for large-scale screening. In terms of our product pipeline, we received the Class II medical device registration certificate for our desktop fundus camera AI-FUNDUSCAMERA-D from the Shanghai branch of the NMPA in July 2022. Also in July 2022, we received the Wu Wen Jun AI Science & Technology Progress Award (吳文俊人工智能科技進步獎), the highest award for intelligent science and technology in China, for the second time since 2019. This makes us the first medical AI company in China who received this award twice.

Our R&D team has accumulated substantial industry experience and is the foundation of our success. As of June 30, 2022, our R&D team consisted of 130 members, all of whom hold bachelor’s or higher degrees. Our R&D team has deep experience in AI-technologies and medicine with a full spectrum of expertise across deep learning, medicine, computer vision, data analytics, internet service, medical devices, biology and other disciplines. Our R&D team is led by our chief technology officer, Dr. HE Chao, and our chief medical officer, Dr. CHEN Yuzhong.

Manufacturing

To better meet our customers’ increasing demands for different types of fundus cameras, we start to prepare ourselves with our own manufacturing capabilities and will shift to manufacture our hardware devices in house going forward. During the Reporting Period, we started to build our own manufacturing facilities, but still engaged OEM service providers to manufacture our hardware devices. We adopted procedures to ensure that the production qualifications, facilities and processes of these OEM service providers comply with the relevant regulatory requirements and our internal guidelines. We selected our OEM service providers by reviewing a number of factors, including their qualification, expertise, technologies and equipment. We had no difficulty engaging OEM service providers during the Reporting Period. With our own manufacturing facilities now in place, we are ready to produce hardware devices by ourselves since the second half of 2022.



Management Discussion and Analysis (Continued)

We purchase raw materials for the production of our self-developed fundus cameras, such as plastic molds, metal components and PCBA. As of June 30, 2022, such fundus cameras were produced in factories operated by these OEM service providers. Pursuant to our agreements with these OEM service providers, they were responsible for assembling and ensuring the compliance with regulatory standards. We typically will decide whether to accept the supply upon inspecting and examining the products and pay the OEM service providers after the receipt and inspection of products. In general, OEM service providers will provide complimentary after-sales services to us within the warranty periods, except for those whose warranty periods have expired, in which case they may charge a service fee for the cost of their repair services.

Our Commercialization Progress

Our portfolio of AI-empowered retina-based early detection, diagnosis and health risk assessment solutions has potentially broad applications and coverage of a wide range of chronic diseases. Given the wide range of healthcare environments that can use our products, we have developed a flexible and multi-channel sales and marketing strategy to cover various commercialization pathways in medical institutions, consumer healthcare environments and eye health management settings.

During the Reporting Period, the number of our customers increased year-over-year to 265 from 83 in the same period last year. With a monthly average of over 2,300 service sites where our SaMDs and health risk assessment solutions were used by our customers to serve end users day to day, we detected a total number of 1,632,753 cases (“Uses”) during the Reporting Period, representing a year-over-year decrease of 34.8%. The decrease was primarily due to the restrictions of social activities, such as temporary closure of business and stay-at-home orders, imposed in several cities across China in response to the evolving COVID-19 pandemic. Such containment measures adversely affected the usage of our AI-based software solutions especially through the second quarter of 2022 as some service sites in several cities were temporarily closed. Amidst such environment, however, we also saw that the usage had bottomed out in April and rebounded with a continued growing momentum since then as this round of outbreak was gradually fading.

For our provision of SaMDs or health risk assessment solutions, we charge our customers on a pay-per-use basis based on the actual amount of testing services we provided, or charge our customers a preset fee for a predetermined or unlimited amount of testing services during the subscription period pursuant to the service agreements with our customers. For the Reporting Period, we charged an average of RMB19.3 per Use, which is calculated by dividing our revenue from the provision of AI-based software solutions by the Uses, representing a year-over-year increase of 13.6% from RMB17.0 per Use for the same period last year.

We had established an in-house sales and marketing team of 161 members as of June 30, 2022 to provide our customers with a full life cycle of customized supports. Our sales and marketing team which comprises functions of sales, product solution and customer success covers different geographic regions and different commercialization channels. We provide our sales and marketing personnel with comprehensive training covering our corporate culture, product knowledge, medical theories and marketing system, etc.



Management Discussion and Analysis (Continued)

Airdoc Medical

Airdoc Medical covers medical institutions which include hospitals, primary healthcare institutions (such as community clinics) and health checkup centers. Aiming to be of great help to eye doctors and address the issue of lack of experienced retinal specialists in underserved regions, our solution for Airdoc Medical primarily serves the clinical needs for detection and auxiliary diagnosis of certain indications with quantitative measurements, such as the total size and number of hemorrhages and exudates. For example, we promote our Airdoc-AIFUNDUS to medical institutions to assist physicians with medical diagnoses and target patients with chronic diseases covered by our Airdoc-AIFUNDUS. In August 2020, we received the Class III medical device registration certificate from the NMPA for our Airdoc-AIFUNDUS (1.0), the SaMD approved for the auxiliary diagnosis of diabetic retinopathy. We have started the commercialization of our Airdoc-AIFUNDUS (1.0) since early 2021.

For our sales to hospitals, we will seek to include our Airdoc-AIFUNDUS (1.0) in the pricing guidance in most provinces in China, upon which hospitals can charge patients separately for such medical service. As of the date of this interim report, the pricing guidance of fundus image analysis in large populations had been issued by local governmental authorities in Hebei, Shandong, Shanxi, Anhui and Jiangsu, pursuant to which our Airdoc-AIFUNDUS can be utilized as a new charging item. We are currently working on assisting several hospitals across multiple provinces to obtain the pricing guidance. Depending on the evolving healthcare-related policies and regulations adopted by various local governments, we may adjust from time to time the strategy in term of in which province we apply for the pricing guidance in order to obtain it as soon as possible. Although our expected applying progress has been adversely affected by the intensified containment measures in response to the development of the COVID-19 pandemic, we managed to assist the hospitals in Beijing and Jilin to apply for the pricing guidance in the first half of 2022. As of the date of this interim report, we are also assisting hospitals in Hubei, Hunan and Jiangxi with the applying. For primary healthcare institutions and health checkup centers, we also market our health risk assessment solutions.

We are dedicated to increasing our penetration in hospitals across the country while expanding our coverage of primary healthcare institutions which represent the majority of medical institutions in China. For the Reporting Period, we had sold our Airdoc-AIFUNDUS (1.0) to 41 hospitals and 50 primary healthcare institutions, with the monthly average number of service sites related to hospitals and primary healthcare institutions increased year-over-year by over 230%. In addition, we also implemented our AI-based solutions in over 160 health checkup centers across China. For the Reporting Period, we recorded revenue of RMB12.6 million from Airdoc Medical and generated revenue of RMB9.5 million from the sales of our Airdoc-AIFUNDUS (1.0).

Airdoc Health

Airdoc Health covers a wide range of consumer healthcare environments, such as insurance companies and pharmacies, to which we offer our health risk assessment solutions that focus on chronic diseases. As the concept of health management is on the rise, more types of business settings have emerged as the entry point of daily health management for specific populations, and they are keen to better serve their end users' specific healthcare needs. This is where we can perfectly fit in. With our solution for Airdoc Health, we empower consumer healthcare environments to provide the AI-enabled assessment of risk factors for chronic diseases and continuous health monitoring, allowing high-quality healthcare accessible in a much wider range of business settings and to a much larger base of end users.



Management Discussion and Analysis (Continued)

In the business setting of insurance, we assist insurance companies in evaluating the health conditions of their insurance applicants and insured members in an accurate, efficient and continuous manner. For example, we helped one of our insurance customers build health stations at its branch offices where its end customers can take regular health checkups. To explore additional business opportunities in the insurance industry, we are expanding our cooperation with insurance companies from life insurance to more types of insurance, such as health insurance and group insurance. During the Reporting Period, we had provided our solutions to over 40 insurance companies, among which many were top commercial insurance companies. In the business setting of pharmacy, we enable pharmacy chains and pharmaceutical companies to utilize pharmacies as a landing point for various healthcare services and managing chronic diseases in the healthcare ecosystem. During the Reporting Period, our health risk assessment solutions was used by over 700 pharmacies across the country with the monthly average number of service sites increased year-over-year by over 470%. In addition, we continue exploring business opportunities in government well-being projects where we assist local governments with the large-scale screening of chronic diseases. For the Reporting Period, we recorded revenue of RMB17.2 million from Airdoc Health.

Airdoc Eye Health

Airdoc Eye Health covers various eye health management settings, such as optometry centers and government-backed vision screening projects, to which we offer our health risk assessment solutions that focus on retinal conditions and eye diseases. People's eye health awareness in general is being raised along with the development of eye care infrastructure. Myopia control and prevention in particular has become not only a national campaign promoted by the government, but also an activity that parents would prioritize to conduct as their children are facing with more schoolwork. With our solution for Airdoc Eye Health, we address the needs for eye health evaluation as well as myopia control and prevention. For optometry centers, we provide our customers with a comprehensive analysis of their end customers' retinal conditions, enabling them not only to identify risk factors that may lead to impaired vision, but also provide customized professional eyeglasses prescriptions. During the Reporting Period, our solutions had been deployed in over 1,000 optometry centers across China with the monthly average number of service sites increased year-over-year by over 17%. For the Reporting Period, we recorded revenue of RMB7.6 million from Airdoc Eye Health.

Future and Outlook

The COVID-19-related restrictions of social activities had a significant adverse impact on our business operations during the Reporting Period, especially in the second quarter of 2022. Although we managed to further expand our customer base as compared with last year, the temporary closure of service sites experienced by some of our customers and people's reluctance to meet face-to-face under such circumstances still materially reduced the usage of our products and services at offline service sites. On one hand, we have seen the recovery momentum in our Uses as this round of COVID-19 outbreak is receding. But on the other hand, our growth trajectory would still to some extent depend on the evolving situation of the pandemic in the second half of 2022. Despite all challenges, we will further execute our business strategy of multi-faceted commercialization and better cater to different types of customers across Airdoc Medical, Airdoc Health and Airdoc Eye Health, not only to capture market opportunities in various healthcare service settings but to make high-quality healthcare accessible and affordable to everyone. In addition to these three key business pillars that support our business expansion domestically, we will also continue to explore growth opportunities in overseas markets. With initial results achieved in a few countries such as Indonesia, Malaysia and South Africa, we also gained market access in the United States and European Union for our own fundus cameras in late June 2022. Based on the full suite of integrated AI-based software and hardware solution that has established commercialization pathways in China, we aim to increase our global coverage as well in more countries in the years to come.

Management Discussion and Analysis (Continued)

FINANCIAL REVIEW

Revenue

During the Reporting Period, we primarily generated revenue from three business pillars, which are Airdoc Medical, Airdoc Health and Airdoc Eye Health, by providing customers with our integrated AI-based software and hardware solutions. We offer AI-based software solutions by providing SaMDs to medical institutions and providing health risk assessment solutions to various healthcare providers. Depending on customer needs, we may sell our software as a standalone product, or as a bundle with our proprietary or third-party hardware if those customers who want to buy our software do not own any fundus camera in the first place. We also provided our customers with other services which primarily include procurement services we provided to some of our customers for the third-party hardware devices and software development services we provided to our customers according to their customization requirements.

Our revenue was RMB37.4 million for the six months ended June 30, 2022, compared with RMB49.5 million for the six months ended June 30, 2021. The decrease was primarily due to a decrease in revenue from the provision of AI-based software solutions as a result of a decreasing number of Uses of our SaMDs and health risk assessment solutions amidst the restrictions of social activities in response to the evolving COVID-19 pandemic. The following table sets forth a breakdown of our revenue by customer type for the periods indicated.

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(unaudited)	(unaudited)
Airdoc Medical	12,577	10,349
Airdoc Health	17,223	28,673
Airdoc Eye Health	7,607	10,455
Total	37,407	49,477

Cost of Sales

Our cost of sales primarily consists of (i) depreciation expenses which primarily relate to the depreciation of hardware devices; (ii) hardware devices costs which represent the purchase costs of fundus cameras from third parties that were used with our software; (iii) employee benefits expenses; and (iv) cloud service fees which represent the service fees we paid to cloud service suppliers to support our AI-based software solutions.

Our cost of sales was RMB15.3 million for the six months ended June 30, 2022, compared with RMB17.8 million for the six months ended June 30, 2021. This decrease was generally in line with the decrease in sales of our AI-based software solutions and hardware devices, partially offset by an increase of depreciation expenses incurred as more fundus cameras were manufactured in the second half of 2021 to support our business expansion.

Management Discussion and Analysis (Continued)

Gross Profit and Gross Profit Margin

Based on the factors described above, the gross profit of the Group was RMB22.1 million for the six months ended June 30, 2022, compared with RMB31.7 million for the six months ended June 30, 2021. Gross profit margin is calculated as gross profit divided by revenue. The overall gross profit margin of the Group was 59.0% for the six months ended June 30, 2022, compared with 64.1% for the six months ended June 30, 2021. The decrease of gross profit margin was primarily due to the disproportion between decreases in revenue and cost of sales as some cost items are fixed costs. For the Reporting Period, the gross profit margin of our AI-based software solutions was 65.5%.

Other Income

Our other income significantly increased to RMB28.6 million for the six months ended June 30, 2022 from RMB4.1 million for the six months ended June 30, 2021, primarily due to a net foreign exchange gain of RMB40.8 million while partially offset by losses incurred from forward exchange contracts.

R&D Expenses

Our R&D expenses primarily consist of (i) employee benefits expenses for our employees involved in R&D; (ii) product development expenses, representing expenses incurred for AI studies, R&D activities, technical services, medical equipment and testing services; (iii) product registration expenses; (iv) depreciation expenses in relation to our R&D equipment and facilities; and (v) others, which primarily include leasing expenses for our R&D facilities, travel expenses, utilities expenses and other general office expenses for R&D activities. The following table sets forth a breakdown of our R&D expenses for the periods indicated.

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(unaudited)	(unaudited)
Employee benefits expenses	47,771	17,324
Product development expenses	13,549	3,550
Product registration expenses	4,451	887
Depreciation expenses	2,171	1,185
Others	1,631	1,059
Total	69,573	24,005

Our R&D expenses was RMB69.6 million for the six months ended June 30, 2022, compared with RMB24.0 million for the six months ended June 30, 2021. The increase was primarily due to an increase in employee benefits expenses as a result of the expansion of our R&D team, as well as our continuing investment in the fast-growing product pipeline of AI-based software solutions and hardware devices.



Management Discussion and Analysis (Continued)

Selling Expenses

Our selling expenses primarily consist of employee benefits expenses for our in-house sales and marketing team as well as marketing expenses.

Our selling expenses was RMB48.9 million for the six months ended June 30, 2022, compared with RMB23.6 million for the six months ended June 30, 2021. The increase was primarily due to an increase in employee benefits expense along with the expansion of our sales and marketing team, the additional members of which were mostly recruited in the second half of 2021 to provide customized services and support to different clienteles across various sales channels.

Administrative Expenses

Our administrative expenses mainly consist of employee benefits expenses for our employees involved in administrative and supportive functions as well as professional service expenses.

Our administrative expenses was RMB31.7 million for the six months ended June 30, 2022, compared with RMB25.2 million for the six months ended June 30, 2021. The increase was primarily due to an increase in employee benefits expense resulting from the expansion of our back office team, the additional members of which were mostly recruited in the second half of 2021 to support our growing business.

Income Tax

We recorded income tax of nil for the six months ended June 30, 2022 (June 30, 2021: RMB0.3 million).

Loss for the Period

We recorded a loss of RMB99.7 million for the six months ended June 30, 2022, compared with a loss of RMB37.5 million for the six months ended June 30, 2021.

Property, Plant and Equipment

Our property, plant and equipment primarily consists of (i) hardware devices, representing the fundus cameras which have been deployed or will be deployed at our customers' service sites to be used together with our software; (ii) furniture and others; (iii) right-of-use assets, representing the leasing of our offices; and (iv) leasehold improvement.

Our property, plant and equipment decreased to RMB40.2 million as of June 30, 2022, compared with RMB45.0 million as of December 31, 2021, which was primarily due to an increase in depreciation of our hardware devices.



Management Discussion and Analysis (Continued)

Inventories

Our inventories primarily consist of raw materials for manufacturing our self-developed fundus cameras and the third-party fundus cameras we purchased for the bundled sales together with our software. We assign specific personnel to regularly monitor our inventories and endeavor to keep an optimal inventory level in line with the expected usages in the near term.

Our inventories increased to RMB11.9 million as of June 30, 2022, compared with RMB7.7 million as of December 31, 2021. The increase was primarily because we procured more third-party fundus cameras for the developing of new customers and purchased more raw materials for the manufacturing of our in-house developed fundus cameras.

Trade Receivables

Our trade receivables increased to RMB43.7 million as of June 30, 2022, compared with RMB34.0 million as of December 31, 2021. The increase was primarily due to a relatively slower payment collection from our customers whose business operations were also adversely affected by the COVID-19 pandemic.

Deposits, Prepayments and Other Receivables

Our deposits, prepayments and other receivables decreased to RMB15.3 million as of June 30, 2022, compared with RMB19.2 million as of December 31, 2021. The decrease was primarily due to a decrease in prepayments to suppliers in relation to the purchase of third-party fundus cameras and marketing services as the fundus cameras were received and services were fulfilled.

Cash and Cash Equivalents

Our cash and cash equivalents decreased to RMB1,421.3 million as of June 30, 2022, compared with RMB1,784.6 million as of December 31, 2021. The decrease was primarily attributable to the initiation of a bank deposit of RMB150.0 million, certain investment made during the Reporting Period and the use of cash in the ordinary course of business.

Trade and Other Payables

Our trade and other payables decreased to RMB30.1 million as of June 30, 2022, compared with RMB48.5 million as of December 31, 2021. The decrease was primarily attributable to a decrease in payables relating to the listing expenses.

Liquidity and Source of Funding

Our policy is to regularly monitor our liquidity requirements and our compliance with lending covenants, to ensure that we maintain sufficient reserves of cash and adequate committed lines of funding from major financial institutions to meet our liquidity requirements in the short and longer term.

As of June 30, 2022, our current assets were RMB1,743.1 million which mainly includes cash and cash equivalents of RMB1,421.3 million, bank deposits of RMB150.0 million and other financial assets of RMB100.9 million. As of June 30, 2022, our current liabilities were RMB50.8 million which mainly includes trade and other payables of RMB30.1 million and contract liabilities of RMB15.3 million.



Management Discussion and Analysis (Continued)

Borrowings

As of June 30, 2022, we did not have any bank loans or other borrowings (as of December 31, 2021: nil).

Contract Liabilities

Our contract liabilities represent our obligations to transfer services to our customers as we entered into services agreements with our customers for AI-based software solutions and sales of hardware devices for which we have received advanced payments from such customers under the relevant customer service agreements or work orders.

Our contract liabilities decreased to RMB15.3 million as of June 30, 2022, compared with RMB17.1 million as of December 31, 2021. The decrease was primarily attributable to a decrease in the short-term advances we received from customers for new contracts signed as well as due to the continuing fulfillment of contract obligations as per the contract terms.

Net Current Assets

Our net current assets decreased to RMB1,692.3 million as of June 30, 2022, compared with RMB1,774.8 million as of December 31, 2021.

Gearing Ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of June 30, 2022, the Company was in a net cash position and thus gearing ratio is not applicable.

Treasury Policy

We adopt a prudent financial management approach for our treasury policy to ensure that our liquidity structure comprising assets, liabilities and other commitments is able to always meet our capital requirements.

Other Information

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY OF ITS ASSOCIATED CORPORATIONS

As of June 30, 2022, the interests and short positions of the Directors, Supervisors or chief executives of the Company and their associates in any of the Shares, underlying Shares and debentures of our Company or its associated corporation (within the meaning of Part XV of the SFO), as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

Long Positions in the Shares or underlying Shares of the Company

Name of Director	Position	Nature of interest	Number and class of Shares	Approximate percentage of interest in the relevant class of Shares of our Company ⁽¹⁾	Approximate percentage of interest in our Company ⁽²⁾
Mr. Zhang	Executive Director and chief executive officer	Beneficial owner	17,248,854 Domestic Shares	22.22%	16.65%
		Interest in a controlled corporation ⁽²⁾	5,331,308 Domestic Shares	6.87%	5.15%
		Interest of a party to an agreement ⁽³⁾	2,796,117 Domestic Shares	3.60%	2.70%
Mr. Gao	Executive Director	Beneficial owner	883,357 Domestic Shares	1.14%	0.85%
		Interest of a party to an agreement ⁽⁴⁾	24,492,922 Domestic Shares	31.55%	23.65%

Notes:

- (1) The percentage is calculated based on the number of relevant class of Shares in issue as of June 30, 2022.
- (2) The percentage is calculated based on the total number of Domestic Shares and H Shares in issue as of June 30, 2022.
- (3) As of June 30, 2022, Mr. Zhang was the general partner of Airdoc Universe. Therefore, Mr. Zhang was deemed to be interested in the Shares held by Airdoc Universe under the SFO.
- (4) As of June 30, 2022, pursuant to the Concert Party Agreement, Mr. Zhang agreed to act in concert with Mr. Gao and Mr. Chen by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Zhang was deemed to be interested in an aggregate of 2,796,117 Domestic Shares, consisting of 883,357 Domestic Shares held by Mr. Gao and 1,912,760 Domestic Shares held by Mr. Chen under the SFO.
- (5) As of June 30, 2022, pursuant to the Concert Party Agreement, Mr. Gao agreed to act in concert with Mr. Zhang and Mr. Chen by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Gao was deemed to be interested in an aggregate of 24,492,922 Domestic Shares, consisting of 22,580,162 Domestic Shares held by Mr. Zhang and 1,912,760 Domestic Shares held by Mr. Chen under the SFO.

Other Information (Continued)

Save as disclosed above, as of June 30, 2022, to the best knowledge of the Company, none of the Directors, Supervisors or chief executives of the Company or their associates had or was deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations as recorded in the register required to be kept, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As of June 30, 2022, so far as the Directors or chief executives of the Company are aware, the following persons (other than the Directors or chief executives of the Company or their associates) had interests and/or short positions in the Shares or underlying Shares as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Long Positions in the Shares or underlying Shares of Company

Name of Substantial Shareholders	Nature of interest	Number of Shares	Class of Shares	Approximate percentage of interest in the relevant class of Shares of our Company ⁽¹⁾	Approximate percentage of interest in our Company ⁽²⁾
Mr. Chen	Beneficial owner	1,912,760	Domestic Shares	2.46%	1.85%
	Interest of a party to an agreement ⁽¹⁾	23,463,519	Domestic Shares	30.22%	22.65%
Fosun International ⁽²⁾	Interest in a controlled corporation	10,386,756	Domestic Shares	13.38%	10.03%
Yadong Beichen ⁽²⁾⁽³⁾	Beneficial owner	10,272,503	Domestic Shares	13.23%	9.92%
	Interest of a party to an agreement	114,253	Domestic Shares	0.15%	0.11%
Ping An Insurance ⁽⁴⁾	Interest in a controlled corporation	7,169,737	Domestic Shares	9.24%	6.92%
Ping An Healthtech ⁽⁴⁾	Beneficial owner	7,169,737	Domestic Shares	9.24%	6.92%
Ms. XU Yanhua ⁽⁵⁾	Interest in a controlled corporation	6,486,253	Domestic Shares	8.25%	6.26%
Suqian Airdoc ⁽⁵⁾	Beneficial owner	4,166,665	Domestic Shares	5.37%	4.02%
Mr. MA Huateng ⁽⁶⁾	Interest in a controlled corporation	5,942,699	Domestic Shares	7.65%	5.74%
Tencent Holdings Limited ⁽⁶⁾	Interest in a controlled corporation	5,942,699	Domestic Shares	7.65%	5.74%
Shiji Sisu ⁽⁶⁾	Beneficial owner	5,942,699	Domestic Shares	7.65%	5.74%

Other Information (Continued)

Name of Substantial Shareholders	Nature of interest	Number of Shares	Class of Shares	Approximate percentage of interest in the relevant class of Shares of our Company ⁽¹⁾	Approximate percentage of interest in our Company ⁽²⁾
Lake Bleu Capital (Hong Kong) Investment manager Limited ⁽⁷⁾	Investment manager	5,049,236	H Shares	19.47%	4.88%
China Life Franklin Asset Management Co., Limited ⁽⁸⁾	Investment manager	3,107,000	H Shares	11.98%	3.00%
China Life Insurance (Group) Company ⁽⁸⁾⁽⁹⁾	Beneficial owner Interest in a controlled corporation	155,400	H Shares	0.60%	0.15%
		2,951,600	H Shares	11.38%	2.85%
China Life Insurance (Overseas) Co., Ltd. ⁽⁸⁾⁽⁹⁾	Beneficial owner	2,951,600	H Shares	11.38%	2.85%
Dr. Yi SHI ⁽¹⁰⁾	Interest in a controlled corporation	2,607,336	H Shares	10.05%	2.52%
LAV ImmOn Hong Kong Limited ⁽¹⁰⁾	Beneficial owner	1,571,536	H Shares	6.05%	1.52%
UBS Group AG ⁽¹¹⁾	Interest in a controlled corporation	1,570,899	H Shares	6.06%	1.52%
UBS AG ⁽¹¹⁾	Beneficial owner	1,550,900	H Shares	5.98%	1.50%

Notes:

- (1) The percentage is calculated based on the number of relevant class of Shares in issue as of June 30, 2022.
- (2) The percentage is calculated based on the total number of Domestic Shares and H Shares in issue as of June 30, 2022.
- (3) As of June 30, 2022, pursuant to the Concert Party Agreement, Mr. Chen agreed to act in concert with Mr. Zhang and Mr. Gao by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Chen was deemed to be interested in an aggregate of 23,463,519 Domestic Shares, consisting of 22,580,162 Domestic Shares held by Mr. Zhang and 883,357 Domestic Shares held by Mr. Gao under the SFO.
- (4) As of June 30, 2022, Yadong Beichen was held by Shanghai Ruikun Venture Capital Co., Ltd. (上海銳坤創業投資有限公司) ("Shanghai Ruikun") and Shanghai Fosun Industrial Investment Co., Ltd. (上海復星產業投資有限公司) ("Shanghai Fosun") as to 64.1% and 35.9%, respectively. Shanghai Ruikun was owned as to 98% by Shanghai Fosun High Technology Group Finance Co., Ltd. (上海復星高科技(集團)有限公司) ("Fosun High Technology") which was wholly owned by Fosun International Limited (復星國際有限公司) ("Fosun International"), a company whose shares are listed on the Stock Exchange (stock code: 656). Shanghai Fosun was wholly owned by Fosun High Technology. Therefore, each of Shanghai Ruikun, Shanghai Fosun, Fosun High Technology and Fosun International was deemed to be interested in the 10,386,756 Domestic Shares in which Yadong Beichen was interested under the SFO.
- (5) As of June 30, 2022, pursuant to the voting proxy arrangement between Ningbo Xingbangyu Business Management Consulting Partnership (Limited Partnership) (寧波星邦鬱企業管理諮詢合夥企業(有限合夥)) ("Xingbangyu") and Yadong Beichen, Xingbangyu conferred the voting right of the Shares held by it on Yadong Beichen. Therefore, Yadong Beichen was deemed to be interested in the 114,253 Domestic Shares held by Xingbangyu under the SFO.



Other Information (Continued)

- (6) As of June 30, 2022, Ping An Healthtech was wholly owned by Ping An Technology (Shenzhen) Co., Ltd. (平安科技(深圳)有限公司) (“**Ping An Technology**”), which was owned by Ping An Insurance (Group) Company of China, Ltd. (中國平安保險(集團)股份有限公司) (“**Ping An Insurance**”), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 601318), and Shenzhen Ping An Financial Technology Consulting Co., Ltd. (深圳平安金融科技諮詢有限公司) (“**Ping An Financial**”) as to 68.4% and 31.6%, respectively. Therefore, each of Ping An Technology, Ping An Insurance and Ping An Financial was deemed to be interested in the 7,169,737 Domestic Shares held by Ping An Healthtech under the SFO.
- (7) As of June 30, 2022, Ms. XU Yanhua (徐彥華), an employee of our Group, was the general partner of Suqian Airdoc and Suqian Zhongyou, each as an employee incentive platform of our Company. Therefore, Ms. XU Yanhua is deemed to be interested in the 4,166,665 and 2,319,588 Domestic Shares respectively held by Suqian Airdoc and Suqian Zhongyou under the SFO.
- (8) As of June 30, 2022, Shiji Sisu was wholly owned by Sogou Information, which was ultimately beneficially owned as to 55% by Mr. MA Huatong and 45% by Tencent Holdings Limited, a company whose shares are listed on the Stock Exchange (stock code: 700). Therefore, each of Sogou Information, Mr. MA Huatong and Tencent Holdings Limited was deemed to be interested in the 5,942,699 Domestic Shares held by Shiji Sisu under the SFO.
- (9) As of June 30, 2022, Lake Bleu Capital (Hong Kong) Limited was the investment manager of Lake Bleu Prime Healthcare Master Fund Limited and LBC Sunshine Healthcare Fund II. Limited Partnership, which holds 3,477,700 H Shares and 1,571,536 H Shares, respectively. Therefore, Lake Bleu Capital (Hong Kong) Limited is deemed to be interested in the Shares in which Lake Bleu Prime Healthcare Master Fund Limited and LBC Sunshine Healthcare Fund II. Limited Partnership were interested under the SFO.
- (10) As of June 30, 2022, China Life Insurance (Overseas) Co., Ltd directly held 2,951,600 H Shares and was wholly owned by China Life Insurance (Group) Company. China Life Insurance (Group) Company directly held 155,400 H Shares of the Company, and was deemed interested in the 2,951,600 H Shares held by China Life Insurance (Overseas) Co., Ltd. China Life Franklin Asset Management Co., Limited was the investment manager of China Life Insurance (Group) Company and therefore was deemed to be interested in an aggregate of 3,107,000 H Shares in which China Life Insurance (Group) Company and China Life Insurance (Overseas) Co., Ltd. were interested under the SFO.
- (11) As of June 30, 2022, China Life Insurance (Overseas) Co., Ltd. was wholly owned by China Life Insurance (Group) Company. Therefore, China Life Insurance (Group) Company was deemed to be interested in the 2,951,600 H Shares held by China Life Insurance (Overseas) Co., Ltd. under the SFO.
- (12) As of June 30, 2022, LAV Star Limited was wholly-owned by LAV Fund VI, L.P. and LAV Star Opportunities Limited was wholly-owned by LAV Fund VI Opportunities, L.P. (together with LAV Fund VI, L.P., collectively, the “**LAV Fund VI**”). LAV Star Limited and LAV Star Opportunities Limited were associated with LAV ImmOn Hong Kong Limited. LAV ImmOn Hong Kong Limited and LAV Fund VI were ultimately beneficially owned by Dr. Yi SHI. Therefore, Dr. Yi SHI was deemed to be interested in an aggregate of 2,607,336 H Shares, consisting of 517,900 H Shares held by LAV Star Limited, 517,900 H Shares held by LAV Star Opportunities Limited and 1,571,536 H Shares held by LAV ImmOn Hong Kong Limited, under the SFO.
- (13) As of June 30, 2022, UBS AG and UBS Switzerland AG were wholly owned by UBS Group AG. Therefore, UBS Group AG was deemed to be interested in an aggregate of 1,570,899 H Shares, consisting of 1,550,900 H Shares held by UBS AG and 19,999 H Shares held by UBS Switzerland AG, under the SFO.

Save as disclosed above, as of June 30, 2022, to the best knowledge of the Company, no person, other than the Directors, Supervisors or chief executives of the Company whose interests are set out in the subsection above, had any interests or short positions in the Shares or underlying Shares as recorded in the register required to be kept under section 336 of the SFO.



Other Information (Continued)

CORPORATE GOVERNANCE

The Company is committed to maintaining high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted the code provisions of the CG code as its own code of corporate governance. During the six months ended 30 June 2022, save as disclosed herein, the Board is of the view that the Company has complied with all applicable code provisions of the CG code and adopted most of the recommended best practices.

Under the code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organization structure of the Company, Mr. Zhang is the chairman of the Board, chief executive officer and founder of the Company. With extensive experience in the medical devices industry and having served in the Company since its establishment, Mr. Zhang is in charge of overall management, business and strategic development of the Group. The Board considers that vesting the roles of the chairman of the Board and the chief executive officer in the same person is beneficial to the business operations and management of the Group. The balance of power and authority is ensured by the operation of the Board, which comprises experienced and diverse individuals. The Board currently comprises four executive Directors (including Mr. Zhang), two non-executive Directors and three independent non-executive Directors, and therefore has a strong independent element in its composition.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance and assess whether separation of the roles of chairman of the Board and chief executive officer is necessary.

DIRECTORS' AND SUPERVISORS' SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors, Supervisors and the Company's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities.

Upon specific enquiry, all Directors and Supervisors confirmed that they have complied with the Model Code during the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group during the Reporting Period.

SHARE CAPITAL AND SHARES ISSUED

Details of movements in the share capital of the Company for the six months ended June 30, 2022 and details of the Shares issued for the six months ended June 30, 2022 are set out in Note 12 to the Unaudited Interim Financial Report.

DEBENTURE ISSUED

The Group did not issue any debenture for the six months ended June 30, 2022.

EQUITY-LINKED AGREEMENTS

No equity-linked agreements that will or may result in the Company issuing shares or that require the Company to enter into any agreements that will or may result in the Company issuing shares were entered into by the Company during the Reporting Period or subsisted at the end of the Reporting Period.

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS

During the six months ended June 30, 2022, we did not make any significant investments or material acquisitions or disposals of subsidiaries, associates and joint ventures.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

As of the date of this interim report, we did not have any existing plan for material investments or acquisition of capital assets.

CAPITAL COMMITMENTS

As of June 30, 2022, we did not have any significant capital commitments (as of December 31, 2021: nil).

CONTINGENT LIABILITIES

As of June 30, 2022, we did not have any contingent liabilities.

PLEDGE ON ASSETS

There were no pledges on the Group's assets as of June 30, 2022 (as of December 31, 2021: nil).

FOREIGN EXCHANGE EXPOSURE

Our financial statements are expressed in RMB, but certain of its cash and cash equivalents are denominated in foreign currencies, and are exposed to foreign currency risk. We have established a foreign exchange exposure monitoring policy and will consider hedging against significant foreign exchange exposure of the Group should the need arise.

EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2022, we had 340 full-time employees. The total remuneration cost (share-based compensation included) incurred by the Group for the six months ended June 30, 2022 was RMB102.7 million.

The remuneration package of our employees includes salary and bonus, which are generally determined by their qualifications, industry experience, position and performance. We make contributions to social insurance and housing provident funds as required by the PRC laws and regulations. For the six months ended June 30, 2022, we did not experience any material labor disputes or strikes that may have a material and adverse effect on our business, financial condition or results of operations, or any difficulty in recruiting employees.

Other Information (Continued)

USE OF NET PROCEEDS FROM GLOBAL OFFERING

The Company's Shares were listed on the Stock Exchange on November 5, 2021. After finalization and the settlement of the listing expenses, including the relevant expenses incurred by work done by professional parties, the finalized net proceeds from the Global Offering amounted to HK\$1,550.7 million. Accordingly, the planned applications of the net proceeds as disclosed in the section headed "Future Plans and Use of Proceeds" are adjusted pro rata as set forth in the table below. The planned applications and allocation percentage remained unchanged. As of June 30, 2022, approximately HK\$173.9 million of the net proceeds of the Global Offering had been utilized as follows:

Use of proceeds	Planned applications (HK\$ million)	Percentage of total net proceeds (%)	Actual usage for	Actual usage up	Unutilized	Expected time of full utilization of remaining balance
			the six months ended June 30, 2022 (HK\$ million)	to June 30, 2022 (HK\$ million)	net proceeds as of June 30, 2022 (HK\$ million)	
Optimization, development and commercialization of our Core Product	775.4	50%	117.6	117.7	657.7	2026
Research and development and manufacturing of our hardware devices	294.6	19%	23.7	23.7	270.9	2026
Ongoing and future R&D of our health risk assessment solutions	155.1	10%	11.4	11.4	143.7	2026
Development of our portfolio to diversify our AI-empowered retina-based early detection, diagnosis and health risk assessment solutions	93.0	6%	9.6	9.6	83.4	2024
Collaborations with academic and research institutions on joint research projects	77.5	5%	0.2	0.2	77.3	2024
Working capital and other general corporate purposes	155.1	10%	5.3	11.3	143.8	2024
Total	1,550.7	100%	167.8	173.9	1,376.8	

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed herein, there are no important events affecting the Group occurred after the Reporting Period and up to the date of this interim report.

INTERIM DIVIDENDS

The Board does not recommend the payment of interim dividends for the six months ended June 30, 2022 to the Shareholders (June 30, 2021: nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any listed securities of the Company for the six months ended June 30, 2022.

LOAN AGREEMENT WITH COVENANTS RELATING TO SPECIFIC PERFORMANCE OF CONTROLLING SHAREHOLDERS

During the Reporting Period, the Company did not enter into any loan agreement which contains covenants requiring specific performance of Controlling Shareholders.

SHARE INCENTIVES SCHEME

Airdoc Universe, Suqian Airdoc and Suqian Zhongyou were established in the PRC as our employee incentive platforms, and respectively held approximately 5.15%, 4.02% and 2.24% of the total issued Shares as of the date of this interim report. For further details of the employee incentive platforms, please refer to the prospectus of the Company dated October 26, 2021. During the Reporting Period, the Company did not adopt any share incentive scheme subject to the disclosure requirements under Chapter 17 of the Listing Rules.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration for the six months ended June 30, 2022. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the six months ended June 30, 2022.

CHANGES IN THE INFORMATION OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVE OF THE COMPANY

The changes in the information of the Directors, supervisors and chief executive of the Company since the date of the Company's 2021 annual report are set out below:

1. On March 17, 2022, Mr. JIANG Bo (蔣波) has tendered his resignation as a non-executive Director with effect from May 19, 2022, due to other work engagement;
2. On March 17, 2022, Ms. ZHOU Wenjuan (周雯娟) has tendered her resignation as a Supervisor with effect from May 19, 2022, due to other work engagement;
3. On April 30, 2022, Dr. LUO Ting (羅婷) ceased to be an independent director of IAT Automobile Technology Co., Ltd. (阿爾特汽車技術股份有限公司), a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 300825);
4. Mr. CHEN Xin (陳欣) has been appointed as a non-executive Director with effect from May 19, 2022;
5. Dr. LUO Ting (羅婷) has been appointed as a Supervisor with effect from May 19, 2022;
6. On June 30, 2022, Dr. LUO Ting (羅婷) ceased to be an independent director of Beijing Thunisoft Co., Ltd. (北京華宇軟體股份有限公司), a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 300271); and
7. Mr. NG Kong Ping Albert (吳港平) has been appointed as an independent director of Alibaba Group Holding Limited, a company whose shares are listed on the Stock Exchange (stock code: 9988), with effect from August 4, 2022.



Other Information (Continued)

Save as disclosed above, as of the date of this interim report, this is no change in the information of the Directors, supervisors or chief executive of the Company which shall be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

None of the Directors or any of their respective associates were granted by the Company or its subsidiaries any right to acquire shares in, or debentures of, the Company or its subsidiaries, or had exercised any such right during the six months ended June 30, 2022.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations pursuant to Rules 13.20, 13.21 and 13.22 of the Listing Rules during the Reporting Period.

REVIEW OF FINANCIAL STATEMENTS

The Audit Committee comprises three independent non-executive Directors, namely Mr. NG Kong Ping Albert, Mr. HUANG Yanlin and Mr. WU Yangfeng. Mr. NG Kong Ping Albert, being the chairman of the committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Company and overseeing the audit process. The Audit Committee has reviewed the interim results of the Group for the six months ended June 30, 2022 and has recommended for the Board's approval thereof. The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results and interim report of the Group for the six months ended June 30, 2022) of the Group.

APPRECIATION

We wish to express our sincere gratitude to our shareholders and business partners for their continued support, and to our employees for their dedication and hard work.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, August 25, 2022



Review Report



Review report to the board of directors of Beijing Airdoc Technology Co., Ltd.
(Incorporated in China with limited liability)

INTRODUCTION

We have reviewed the interim financial report set out on pages 28 to 43 which comprises the consolidated statement of financial position of Beijing Airdoc Technology Co., Ltd. as of 30 June 2022 and the related consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and condensed consolidated cash flow statement for the six months period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and International Accounting Standard 34, *Interim Financial Reporting*, issued by International Accounting Standards Board (“IASB”). The directors are responsible for the preparation and presentation of the interim financial report in accordance with International Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial information and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2022 is not prepared, in all material respects, in accordance with International Accounting Standard 34, *Interim Financial Reporting*.

KPMG

Certified Public Accountants
8th Floor, Prince’s Building
10 Chater Road
Central, Hong Kong

25 August 2022

Consolidated Statement of Profit or Loss

for the six months ended 30 June 2022 — unaudited
(Expressed in RMB)

	Note	Six months ended 30 June	
		2022 RMB'000	2021 RMB'000
Revenue	4	37,407	49,477
Cost of sales		(15,336)	(17,774)
Gross profit		22,071	31,703
Other income	5	28,593	4,063
Research and development expenses		(69,573)	(24,005)
Selling expenses		(48,857)	(23,602)
Administrative expenses		(31,726)	(25,211)
Loss from operations	6	(99,492)	(37,052)
Finance costs		(192)	(102)
Loss before taxation		(99,684)	(37,154)
Income tax	7	—	(336)
Loss for the period		(99,684)	(37,490)
Attributable to:			
Equity shareholders of the Company		(99,684)	(37,597)
Non-controlling interests		—	107
Loss for the period		(99,684)	(37,490)
Loss per share	8		
Basic and diluted (RMB)		(0.98)	(0.50)

The notes on pages 35 to 43 form part of this interim financial report.

Consolidated Statement of Profit or Loss and Other Comprehensive Income

for the six months ended 30 June 2022 — unaudited
(Expressed in RMB)

	Note	Six months ended 30 June	
		2022 RMB'000	2021 RMB'000
Loss for the period		(99,684)	(37,490)
Other comprehensive income for the period, net of nil tax:			
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of subsidiaries outside the PRC		(76)	42
Other comprehensive income for the period		(76)	42
Total comprehensive income for the period		(99,760)	(37,448)
Attributable to:			
Equity shareholders of the Company		(99,760)	(37,555)
Non-controlling interests		—	107
Total comprehensive income for the period		(99,760)	(37,448)

The notes on pages 35 to 43 form part of this interim financial report.

Consolidated Statement of Financial Position

at 30 June 2022 — unaudited
(Expressed in RMB)

	Note	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Non-current assets			
Property, plant and equipment		40,185	44,959
Other financial assets		3,607	3,607
Prepayments		7,366	—
		51,158	48,566
Current assets			
Inventories		11,867	7,683
Trade receivables	9	43,714	34,043
Deposits, prepayments and other receivables		15,320	19,237
Other financial assets		100,888	—
Bank deposits	10	150,000	—
Cash and cash equivalents	10	1,421,281	1,784,648
		1,743,070	1,845,611
Current liabilities			
Trade and other payables	11	30,120	48,538
Contract liabilities		15,347	17,078
Lease liabilities		4,939	4,775
Current taxation		380	380
		50,786	70,771
Net current assets		1,692,284	1,774,840
Total assets less current liabilities		1,743,442	1,823,406

Consolidated Statement of Financial Position (Continued)

at 30 June 2022 — unaudited
(Expressed in RMB)

	Note	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Non-current liabilities			
Lease liabilities		3,648	3,420
		3,648	3,420
Net assets		1,739,794	1,819,986
Capital and reserves	12		
Share capital		101,248	101,248
Reserves		1,638,546	1,718,738
Total equity		1,739,794	1,819,986

Approved and authorised for issue by the board of directors on 25 August 2022.

Zhang Dalei
Director

Gao Fei
Director

The notes on pages 35 to 43 form part of this interim financial report.

Consolidated Statement of Changes in Equity

for the six months ended 30 June 2022 — unaudited
(Expressed in RMB)

	Share capital RMB'000 (Note 12(b))	Share premium RMB'000	Exchange reserve RMB'000	Fair value reserve (non-recycling) RMB'000	Other reserve RMB'000	Accumulated losses RMB'000	Total RMB'000
At 1 January 2022	101,248	1,827,965	330	1,607	54,394	(165,558)	1,819,986
Changes in equity for the six months ended 30 June 2022:							
Loss for the period	—	—	—	—	—	(99,684)	(99,684)
Other comprehensive income	—	—	(76)	—	—	—	(76)
Total comprehensive income	—	—	(76)	—	—	(99,684)	(99,760)
Contributions from shareholders	—	—	—	—	2,320	—	2,320
Equity-settled share-based transactions	—	—	—	—	17,248	—	17,248
At 30 June 2022	101,248	1,827,965	254	1,607	73,962	(265,242)	1,739,794

Consolidated Statement of Changes in Equity (Continued)

for the six months ended 30 June 2022 — unaudited
(Expressed in RMB)

	Attributable to equity shareholders of the Company								
	Share capital RMB'000	Share premium RMB'000	Exchange reserve RMB'000	Fair value reserve (non-recycling) RMB'000	Other reserve RMB'000	Accumulated losses RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
At 1 January 2021	75,000	330,345	275	1,607	23,909	(22,924)	408,212	238	408,450
Changes in equity for the six months ended 30 June 2021:									
Loss for the period	—	—	—	—	—	(37,597)	(37,597)	107	(37,490)
Other comprehensive income	—	—	42	—	—	—	42	—	42
Total comprehensive income	—	—	42	—	—	(37,597)	(37,555)	107	(37,448)
Issuance of ordinary shares	3,981	234,818	—	—	—	—	238,799	—	238,799
Contributions from shareholders	—	—	—	—	21,672	—	21,672	—	21,672
Acquisition of non-controlling interests	—	—	—	—	345	—	345	(345)	—
At 30 June 2021	78,981	565,163	317	1,607	45,926	(60,521)	631,473	—	631,473

The notes on pages 35 to 43 form part of this interim financial report.

Condensed Consolidated Cash Flow Statement

for the six months ended 30 June 2022 — unaudited
(Expressed in RMB)

	Note	Six months ended 30 June	
		2022 RMB'000	2021 RMB'000
Operating activities			
Cash used in operations		(119,440)	(39,452)
Tax paid		—	(2)
Net cash used in operating activities		(119,440)	(39,454)
Investing activities			
Payment for the purchase of property, plant and equipment		(7,239)	(13,765)
Prepayment for purchase of other long-term assets		(4,500)	—
Redemption of other financial assets		1,068,537	550,000
Payment for purchase of other financial assets		(1,161,876)	(550,000)
Placement of bank deposits with original maturity over three months		(150,000)	—
Other cash flows arising from investing activities		4,846	3,123
Net cash used in investing activities		(250,232)	(10,642)
Financing activities			
Capital contributions received from equity shareholders of the Company		2,320	260,471
Other cash flows arising from financing activities		(2,834)	(9,622)
Net cash (used in)/generated from financing activities		(514)	250,849
Net (decrease)/increase in cash and cash equivalents		(370,186)	200,753
Cash and cash equivalents at 1 January		1,784,648	374,698
Effect of foreign exchanges rates changes		6,819	(166)
Cash and cash equivalents at 30 June	10	1,421,281	575,285

The notes on pages 35 to 43 form part of this interim financial report.

Notes to the Unaudited Interim Financial Report

(Expressed in RMB)

1 GENERAL INFORMATION

Beijing Airdoc Technology Co., Ltd. (北京鷹瞳科技發展股份有限公司) (the “**Company**”) was established as a limited liability company in the People’s Republic of China (the “**PRC**”) on 9 September 2015 and converted into a joint stock limited liability company on 28 December 2020.

The Company and its subsidiaries (together, “**the Group**”) are primarily focusing on providing AI-empowered retina-based early detection, diagnosis and health risk assessment solutions. The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 5 November 2021.

2 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard (“**IAS**”) 34, *Interim Financial Reporting*, issued by the International Accounting Standards Board (“**IASB**”). It was authorised for issue on 25 August 2022.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2021 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2022 annual financial statements. Details of any changes in accounting policies are set out in Note 3.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2021 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with International Financial Reporting Standards (“**IFRSs**”).

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants. KPMG’s review report to the Board of Directors is included in page 27.

3 CHANGES IN ACCOUNTING POLICIES

The Group has applied the following amendments to IFRSs issued by the IASB to this interim financial report for the current accounting period:

- Amendments to IAS 16, *Property, plant and equipment: Proceeds before intended use*
- Amendments to IAS 37, *Onerous Contracts — Costs of Fulfilling a Contract*

These amendments have had no material effect on how to the Group’s results and financial position for the current period have been prepared or presented in the interim financial report.

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

4 REVENUE AND SEGMENT REPORTING

(a) Revenue

The Company derives revenue principally from the provision of AI-based software solutions, sales of hardware devices and other services.

Disaggregation of revenue from contracts with customers within the scope of IFRS 15 by customer type, product type, geographical location of customers and timing of recognition is as follows:

	Six months ended 30 June	
	2022 RMB'000	2021 RMB'000
Disaggregated by customer type		
Medical institutions (Airdoc Medical)	12,577	10,349
Consumer healthcare environments (Airdoc Health)	17,223	28,673
Eye health management settings (Airdoc Eye Health)	7,607	10,455
	37,407	49,477
Disaggregated by major product type		
Provision of AI-based software solutions	31,525	42,600
Sales of hardware devices	5,703	6,001
Other services	179	876
	37,407	49,477
Disaggregated by geographical location of customers		
Mainland China	36,926	49,322
Others	481	155
	37,407	49,477
Disaggregated by timing of revenue recognition		
Point in time	17,185	24,727
Over time	20,222	24,750
	37,407	49,477

(b) Segment reporting

IFRS 8, Operating Segments, requires identification and disclosure of operating segment information based on information that is regularly reviewed by the Group's chief operating decision maker for the purpose of resources allocation and performance assessment. On this basis, the Group has determined that it only has one operating segment during the interim period.

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

5 OTHER INCOME

	Six months ended 30 June	
	2022 RMB'000	2021 RMB'000
Net foreign exchange gain/(loss)	40,848	(208)
Change in fair value of other financial assets	7,549	3,110
Interest income from bank deposits	2,156	1,119
Government grants	217	98
Net loss on disposal of property and equipment	11	(56)
Losses from forward exchange contracts	(22,188)	—
	28,593	4,063

The losses from forward exchange contracts arise from the difference between the contract rate and the exchange rate on the settlement dates.

6 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging:

(a) Finance costs

	Six months ended 30 June	
	2022 RMB'000	2021 RMB'000
Interest on lease liabilities	192	102

(b) Other items

	Six months ended 30 June	
	2022 RMB'000	2021 RMB'000
Depreciation charge	10,897	6,609
Impairment losses/(reversal of impairment losses)		
— trade receivables	707	820
— other receivables	11	(117)
Listing expense	—	2,820
Cost of inventories sold	4,456	5,221
Staff costs		
— salaries, wages and other benefits	85,441	41,092
— share-based payment	17,248	—

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

7 INCOME TAX

	Six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
Current tax – PRC Enterprise Income Tax (“EIT”)		
Provision for the period	—	336

- (i) The PRC statutory income tax rate is 25% to the six months ended 30 June 2022 under the PRC EIT Law. The Group entities in the PRC are subject to PRC income tax at 25% unless otherwise specified.
- (ii) According to the PRC Income Tax Law and its relevant regulations, entities that qualified as high-technology enterprise are entitled to a preferential income tax rate of 15%. Two subsidiaries were recognised as high-technology enterprise and are subject to income tax at 15%.
- (iii) Effective from 1 January 2018 to 31 December 2023, an additional 75% of qualified research and development expenses incurred is allowed to be deducted from taxable income under the PRC Income Tax Law and its relevant regulations.
- (iv) According to the PRC income tax law and its relevant regulations issued in 2019, two entities that qualified as small and low profit enterprise are entitled to a preferential income tax rate of 5% (for taxable income less than RMB1,000,000) or 10% (for taxable income range from RMB1,000,000 to RMB3,000,000).

Taxation for subsidiaries in other tax jurisdictions is charged at the appropriate current rates of taxation ruling in the relevant tax jurisdictions.

8 LOSS PER SHARE

The calculation of the basic loss per share is based on the loss for the period attributable to ordinary equity shareholders of the Company of RMB99,684,000 (six months ended 30 June 2021: loss of RMB37,597,000) and the weighted average of 101,248,000 ordinary shares in issue during the interim period (six months ended 30 June 2021: 75,902,000 shares).

There were no potential dilutive ordinary shares for the period ended 30 June 2022 and 2021, and therefore dilutive loss per share are the same as the basic loss per share.

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

9 TRADE RECEIVABLES

	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Receivables from third parties	44,989	34,693
Receivables from related parties (Note 14(c))	522	440
Less: loss allowance	(1,797)	(1,090)
Trade receivables, net	43,714	34,043

All of the trade receivables are expected to be recovered within one year.

Ageing analyses

The ageing analyses of trade receivables, based on the invoice date and net of loss allowance, are as follows:

	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Within 6 months	28,772	33,174
6 to 12 months	14,942	869
	43,714	34,043

Trade receivables are generally due within 60 to 120 days from the date of billing.

10 CASH AND CASH EQUIVALENTS

	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Cash at bank	1,571,281	1,784,648
Less: Fixed deposits with initial maturity of more than three months	150,000	—
Cash and cash equivalents	1,421,281	1,784,648

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

11 TRADE AND OTHER PAYABLES

	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Trade payables	3,245	5,711
Accrued payroll	13,586	14,843
Other payables and accrued charges:		
— receipt in advance as an agent	724	648
— listing expenses payable	1,768	14,798
— other taxes payable	5,568	4,850
— others	5,229	7,688
	30,120	48,538

All of the above balances classified as current liabilities are expected to be settled within one year.

As at 30 June 2022 and 31 December 2021, the ageing analysis of trade payables presented based on the invoice date is as follows:

	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
Within 6 months	3,245	5,711

12 CAPITAL AND RESERVES

(a) Dividends

The directors of the Company did not propose the payment of any dividend during the interim periods.

(b) Share capital

	Number of ordinary shares '000	Amount RMB'000
Issued and fully paid:		
At 1 January 2021	75,000	75,000
Issuance of ordinary shares (Note (i))	3,981	3,981
Issuance of ordinary shares upon IPO (Note (ii))	22,267	22,267
At 31 December 2021 and 30 June 2022	101,248	101,248

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

12 CAPITAL AND RESERVES (Continued)

(b) Share capital (Continued)

Notes:

- (i) On 30 April 2021, the Company entered into an investment agreement with several independent investors (the “**Series D Investment**”), pursuant to which the investors made a total investment of US\$38,000,000 in the Company as consideration for subscription of 3,981,225 shares of the Company.
- (ii) On 5 November 2021, the Company issued 22,267,200 ordinary shares with a par value of RMB1.00 each, at a price of HK\$75.1 per share upon the listing of the shares on the HK Stock Exchange. The proceeds of RMB22,267,200, representing the par value, were credited to the Company’s share capital. The remaining proceeds of RMB1,285,069,000 (net of share issuance expenses of RMB89,584,000), were credited to the share premium account.

13 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

The following table presents the fair value of the Group’s financial instruments measured at the end of the reporting period on a recurring basis, categorised into the three-level fair value hierarchy as defined in IFRS 13, *Fair value measurement*. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available
- Level 3 valuations: Fair value measured using significant unobservable inputs

The following table presents the Group’s assets that are measured at fair value:

	Fair value at 30 June 2022 RMB’000	Fair value measurements as at 30 June 2022 categorised into		
		Level 1 RMB’000	Level 2 RMB’000	Level 3 RMB’000
Recurring fair value measurement				
Financial assets:				
Unlisted equity securities	3,607	—	3,607	—
Other financial assets (Note (i))	100,888	—	—	100,888

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

13 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (Continued)

	Fair value at 31 December 2021 RMB'000	Fair value measurements as at 31 December 2021 categorised into		
		Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000
Recurring fair value measurement				
Financial assets:				
Unlisted equity securities	3,607	—	3,607	—

Note:

- (i) The fair value of other financial assets was determined based on the quotation from the assets management company.

There were no transfers between Level 1 and Level 2, or transfers into or out of Level 3. The Group's policy is to recognise transfers between levels of fair value hierarchy as at the end of the reporting period in which they occur.

The movements of other financial assets, the measurement of which fall into Level 3 of the fair value hierarchy, during the period are as follows:

	Six months ended 30 June 2022 RMB'000
At 1 January 2022	—
Payment for purchase	1,161,876
Change in fair value	7,549
Proceeds from redemption	(1,068,537)
At 30 June 2022	100,888

Notes to the Unaudited Interim Financial Report (Continued)

(Expressed in RMB)

14 MATERIAL RELATED PARTY TRANSACTIONS

In addition to the related party information disclosed elsewhere in the interim financial report, the Group entered into the following significant related party transactions during the year:

(a) Key management personnel remuneration

Key management personnel are those persons holding positions with authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including the Company's directors.

	Six months ended 30 June	
	2022 RMB'000	2021 RMB'000
Short-term employee benefits	3,114	2,466
Post-employment benefits	165	154
Equity-settled share-based payment	1,190	—
	4,469	2,620

(b) Other significant transactions with related parties

The principal transactions which were carried out in the ordinary course of business are as follows:

	Six months ended 30 June	
	2022 RMB'000	2021 RMB'000
Provision of AI-based software solutions to a fellow subsidiary of a minority shareholder	669	3,972

(c) Balances with related parties as at the end of the reporting period

Details of the outstanding balances with related parties are as follows:

	At 30 June 2022 RMB'000	At 31 December 2021 RMB'000
	Trade related balances due from a fellow subsidiary of a minority shareholder	
— Trade receivables	522	440
— Deposits, prepayments and other receivables	—	30



Definitions and Glossary of Technical Terms

“AI”	artificial intelligence
“Airdoc”, “Group”, “we” or “us”	our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)
“Airdoc Universe”	Beijing Airdoc Universe Technology Center L.P.* (北京鬱金香宇宙科技中心(有限合夥)), a limited partnership established in the PRC on February 22, 2016 and an employee incentive platform of our Group
“ASCVD”	atherosclerotic cardiovascular disease
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Audit Committee”	the audit committee of the Board
“Board” or “Board of Directors”	the board of directors of our Company
“CDR”	cup to disc ratio, a measurement used in ophthalmology and optometry to assess the progression of glaucoma
“China” or “the PRC”	the People’s Republic of China but for the purpose of this interim report and for geographical reference only and except where the context requires, references in this interim report to “China” and the “PRC” do not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Class III medical device”	medical devices with relatively high risks, which shall be strictly controlled and administered through special measures to ensure their safety and effectiveness under the Regulation on the Supervision and Administration of Medical Devices (《醫療器械監督管理條例》)
“CG Code”	the Corporate Governance Code as set out in Appendix 14 to the Listing Rules
“Company”, “our Company” or “the Company”	Beijing Airdoc Technology Co., Ltd. (北京鷹瞳科技發展股份有限公司), a joint stock company incorporated in the PRC with limited liability on September 9, 2015

Definitions and Glossary of Technical Terms (Continued)

“Concert Party Agreement”	the agreement entered into between Mr. Zhang, Mr. Chen and Mr. Gao on October 14, 2016, pursuant to which Mr. Chen and Mr. Gao have undertaken to, among other things, vote unanimously with Mr. Zhang for any resolutions proposed at any Board and Shareholders’ meetings of our Company
“Core Product(s)”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this prospectus, our Core Product refers to our Airdoc-AIFUNDUS
“COVID-19”	a viral respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
“Director(s)”	the director(s) of our Company, including all executive, non-executive and independent non-executive directors
“Domestic Share(s)”	ordinary shares in the share capital of our Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB by domestic investors
“EIT Law”	the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》), as amended, supplemented or otherwise modified from time to time
“Global Offering”	the Hong Kong Public Offering and the International Offering
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“H Share(s)”	overseas listed foreign share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are to be listed on the Stock Exchange and traded in Hong Kong dollars
“ICVD”	ischemic cardiovascular disease, including myocardial infarction and cerebral infarction
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time



Definitions and Glossary of Technical Terms (Continued)

“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 of the Listing Rules
“Mr. Chen”	Mr. Chen Mingqiang (陳明強), one of our co-founders and a member of the single largest group of Shareholders
“Mr. Gao”	Mr. Gao Fei (高斐), one of our co-founders, an executive Director and a member of the single largest group of Shareholders
“Mr. Zhang”	Mr. Zhang Dalei (張大磊), our founder, the chairman of the Board, an executive Director and a member of the single largest group of Shareholders
“NMPA”	the National Medical Products Administration of China (國家藥品監督管理局) or, where the context so requires, its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局), or CFDA
“Nomination Committee”	the nomination committee of the Board
“OEM”	acronym for original equipment manufacturer, a business that manufactures goods or equipment for branding and release by others
“Ping An Healthtech”	Ping An Healthtech Co., Ltd. (平安醫療科技有限公司), a company established in the PRC with limited liability on September 28, 2017
“pricing guidance”	a guidance issued by governmental authorities, which is a pre-requisite for the public hospitals to set specific charging items for medical service and charge patients accordingly
“Reporting Period”	the six months ended June 30, 2022
“Remuneration and Appraisal Committee”	the remuneration and appraisal committee of the Board
“RMB”	Renminbi Yuan, the lawful currency of China
“R&D”	Research and Development

Definitions and Glossary of Technical Terms (Continued)

“SaMD(s)”	Software as a Medical Device, a class of medical software designed to carry out one or more medical functions without the need for actual hardware
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
“Share(s)”	shares in the share capital of our Company, with a nominal value of RMB1.00 each, comprising Domestic Shares and H Shares
“Shareholder(s)”	holder(s) of the Share(s)
“Shiji Sisu”	Beijing Shi Ji Si Su Technology Co., Ltd.* (北京世紀思速科技有限公司), a company established in the PRC with limited liability on May 31, 2009
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Strategy Committee”	the strategy committee of the Board
“subsidiary(ies)”	has the meaning ascribed to it in section 15 of the Companies Ordinance
“Substantial Shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Sogou Information”	Beijing Sogou Information Service Co., Ltd.* (北京搜狗信息服務有限公司), a company established in the PRC with limited liability on December 28, 2005
“Supervisor(s)”	supervisor(s) of our Company
“Suqian Airdoc”	Suqian Airdoc Technology Center (Limited Partnership)* (宿遷鷹瞳科技中心(有限合夥)), a limited partnership established in the PRC on October 13, 2020 and an employee incentive platform of our Group
“Suqian Zhongyou”	Suqian Zhongyou Technology Center (Limited Partnership)* (宿遷眾佑科技中心(有限合夥)), a limited partnership established in the PRC on November 10, 2020 and an employee incentive platform of our Group
“United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction



Definitions and Glossary of Technical Terms (Continued)

“Yadong Beichen”

Yadong Beichen Venture Investment Co., Ltd.* (亞東北辰創業投資有限公司), previously known as Yadong Beichen Investment Management Co., Ltd.* (亞東北辰投資管理有限公司), a company established in the PRC with limited liability on August 2, 2013

For the purpose of this interim report, references to “provinces” of China include provinces, municipalities under direct administration of the central government and provincial-level, autonomous regions.